Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …

Background. Without effective antiviral prophylaxis, cytomegalovirus (CMV) disease is a
common cause of morbidity and mortality after liver transplantation. In this randomized …

Background. We conducted a trial of long-term ganciclovir prophylaxis for prevention of
primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with …

Cytomegalovirus disease is an important cause of morbidity following liver transplantation.
To date there has not been an effective prophylaxis for CMV disease after liver …

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …

This retrospective review compared oral valganciclovir (VGCV) 450 mg daily for 6 months
versus oral ganciclovir (GCV) 1000 mg 3 times daily for 3 months in preventing …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …

Background. The optimal prophylactic regimen to prevent cytomegalovirus (CMV) infection
and disease in orthotopic liver-transplant patients remains to be established. We tested …

Background. The efficacy of pre-emptively administered oral ganciclovir in preventing
cytomegalovirus (CMV) disease has not been documented in liver transplant recipients. We …